MDR1 (also known as P-glycoprotein or ABCB1) can contribute to resistance against MCL1 inhibitors by actively exporting these agents from cancer cells, reducing their intracellular levels and therapeutic efficacy [121]. This evidence concerns the gene MCL1 and cancer.